Drug profile · INN
metoprolol tartrate
METOPROLOL TARTRATE
metoprolol tartrate (METOPROLOL TARTRATE) is a beta-1 adrenergic receptor antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — metoprolol tartrate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
metoprolol tartrate (METOPROLOL TARTRATE) is a beta-1 adrenergic receptor antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is metoprolol tartrate?
metoprolol tartrate (METOPROLOL TARTRATE) is a beta-1 adrenergic receptor antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for metoprolol tartrate?
METOPROLOL TARTRATE is a marketed brand name for metoprolol tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of metoprolol tartrate?
metoprolol tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.